Literature DB >> 25221651

Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.

Elisa Giacomini1, Angela Nebbioso2, Alfonso Ciotta2, Cristina Ianni3, Federico Falchi1, Marinella Roberti3, Manlio Tolomeo4, Stefania Grimaudo5, Antonietta Di Cristina5, Rosaria Maria Pipitone5, Lucia Altucci6, Maurizio Recanatini3.   

Abstract

Given our interest in finding potential antitumor agents and in view of the multifactorial mechanistic nature of cancer, in the present work, taking advantage of the multifunctional ligands approach, new chimeric molecules were designed and synthesized by combining in single chemical entities structural features of SAHA, targeting histone deacetylases (HDACs), with substituted stilbene or terphenyl derivatives previously obtained by us and endowed with antiproliferative and pro-apoptotic activity. The new chimeric derivatives were characterized with respect to their cytotoxic activity and their effects on cell cycle progression on different tumor cell lines, as well as their HDACs inhibition. Among the other, trans -6 showed the most interesting biological profile, as it exhibited a strong pro-apoptotic activity in tumor cell lines in comparison with both of its parent compounds and a marked HDAC inhibition.

Entities:  

Keywords:  HDAC inhibition; Multifunctional ligands; antiproliferative activity; chimeric compound; stilbene

Year:  2014        PMID: 25221651      PMCID: PMC4160757          DOI: 10.1021/ml5000959

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  21 in total

1.  Natural terphenyls: developments since 1877.

Authors:  Ji-Kai Liu
Journal:  Chem Rev       Date:  2006-06       Impact factor: 60.622

2.  Antiproliferative agents that interfere with the cell cycle at the G1-->S transition: further development and characterization of a small library of stilbene-derived compounds.

Authors:  Daniela Pizzirani; Marinella Roberti; Andrea Cavalli; Stefania Grimaudo; Antonietta Di Cristina; Rosaria Maria Pipitone; Nicola Gebbia; Manlio Tolomeo; Maurizio Recanatini
Journal:  ChemMedChem       Date:  2008-02       Impact factor: 3.466

Review 3.  Polypharmacology - foe or friend?

Authors:  Jens-Uwe Peters
Journal:  J Med Chem       Date:  2013-08-22       Impact factor: 7.446

Review 4.  Histone deacetylation in epigenetics: an attractive target for anticancer therapy.

Authors:  Antonello Mai; Silvio Massa; Dante Rotili; Ilaria Cerbara; Sergio Valente; Riccardo Pezzi; Silvia Simeoni; Rino Ragno
Journal:  Med Res Rev       Date:  2005-05       Impact factor: 12.944

Review 5.  Histone deacetylases and cancer.

Authors:  Bruna Barneda-Zahonero; Maribel Parra
Journal:  Mol Oncol       Date:  2012-08-27       Impact factor: 6.603

Review 6.  Multi-targeted histone deacetylase inhibitors in cancer therapy.

Authors:  T Ai; H Cui; L Chen
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 7.  Targeting Histone Deacetylases in Diseases: Where Are We?

Authors:  Rosaria Benedetti; Mariarosaria Conte; Lucia Altucci
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

8.  Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.

Authors:  Marinella Roberti; Daniela Pizzirani; Daniele Simoni; Riccardo Rondanin; Riccardo Baruchello; Caterina Bonora; Filippo Buscemi; Stefania Grimaudo; Manlio Tolomeo
Journal:  J Med Chem       Date:  2003-07-31       Impact factor: 7.446

Review 9.  Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

Authors:  Jennifer S Carew; Francis J Giles; Steffan T Nawrocki
Journal:  Cancer Lett       Date:  2008-05-06       Impact factor: 8.679

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  3 in total

1.  Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.

Authors:  Dong Lu; Juan Yan; Lang Wang; Hongchun Liu; Limin Zeng; Minmin Zhang; Wenwen Duan; Yinchun Ji; Jingchen Cao; Meiyu Geng; Aijun Shen; Youhong Hu
Journal:  ACS Med Chem Lett       Date:  2017-07-18       Impact factor: 4.345

2.  Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.

Authors:  Angela De Simone; Valeria La Pietra; Nibal Betari; Nicola Petragnani; Mariarosaria Conte; Simona Daniele; Deborah Pietrobono; Claudia Martini; Sabrina Petralla; Raffaella Casadei; Lara Davani; Flavia Frabetti; Pasquale Russomanno; Ettore Novellino; Serena Montanari; Vincenzo Tumiatti; Patrizia Ballerini; Federica Sarno; Angela Nebbioso; Lucia Altucci; Barbara Monti; Vincenza Andrisano; Andrea Milelli
Journal:  ACS Med Chem Lett       Date:  2019-02-04       Impact factor: 4.345

3.  Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity.

Authors:  Qian Zhao; Shan-Shan Xiong; Can Chen; Hong-Ping Zhu; Xin Xie; Cheng Peng; Gu He; Bo Han
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.